Sage Journals: Discover world-class research

Abstract

A broad spectrum of chemical entities have been associated with drug-induced seizure (DIS), emphasizing the importance of this potential liability across various drug classes (e.g., antidepressants, antipsychotics, antibiotics, and analgesics among others). Despite its importance within drug safety testing, an understanding of the molecular mechanisms associated with DIS is often lacking. The etiology of DIS is understood to be a result of either a deficit in inhibitory (e.g., gamma aminobutyric acid) or an elevated excitatory (e.g., glutamate) signaling, leading to synchronous neuronal depolarization affecting various brain regions and impairing normal neurological functions. How this altered neuronal signaling occurs and how these changes interact with other non-brain receptor driven DIS-associated changes such as metabolic disturbances, electrolyte imbalances, altered drug metabolism, and withdrawal effects are poorly understood. Herein, we discuss important molecular mechanisms identified in DIS for several drugs and/or drug classes. With a better understanding of the molecular mechanisms associated with DIS, in vivo or in vitro models may be applied to characterize and mitigate DIS risk during drug development. Susceptibility stratification for DIS presents species differences in the following order beagle dogs > rodents and cynomolgus monkeys > Göttingen minipigs with a more than 2-fold difference between canines and minipigs, which is important to consider during non-clinical species selection. While clinical signs such as myoclonus, severe muscle jerks, or convulsions are often associated with abnormal epileptiform EEG activity, tremors are most of the time physiological and rarely observed with concurrent epileptiform EEG activity which need to be considered during DIS risk evaluation.

Keywords

drug-induced seizure convulsion neurotransmission drug attrition adverse drug reaction

Introduction

Drug attrition rates for central nervous system (CNS) diseases are high when compared to other indications.^1-4 In an attempt to better detect and ultimately mitigate adverse drug reactions (ADR), the International Conference on Harmonisation (ICH) S7A guidelines⁵ were adopted which provided a framework under which drug safety pharmacology evaluations are to be conducted. Since the implementation of the ICH S7A guidelines (ca. 2001), no marketed pharmaceutical has been withdrawn due to seizurogenic potential and only one marketed pharmaceutical withdrawal has occurred as a result of a central nervous system (CNS) liability (i.e., Rimonabant for neuropsychiatric adverse events including suicide and depression).⁶ However, drug attrition rates remain high during premarket CNS drug development with the likelihood of approval for neurological indications from Phase 1 trials onward at approximately 10%.^4,7 This is due, in large part, to CNS ADR which include, among others, psychiatric (e.g., fatigue, depression, and suicidal ideation) and nervous system (e.g., neuroleptic malignant syndrome) disorders, neurotoxicity, neuropathies, and neurological impairment/dysfunction (e.g., seizures, learning and memory deficits).^3,8,9

Drug-Induced Seizures

Drug-induced seizure (DIS) is a relatively well characterized adverse effect which can be observed in non-clinical studies but also in the clinical setting.^1,10 DIS are seizures precipitated by the pharmacological and/or toxicological effects of a given chemical entity following acute or chronic exposure or withdrawal. Pharmaceutical agents targeting CNS disorders show the highest propensity for DIS given the high blood brain barrier permeability. However, many pharmacological classes and therapeutic areas (e.g., antibacterial, antivirals, cardiovascular agents, immunosuppressives, and NSAIDs) are known to possess, or be susceptible to, seizure liability risks^11,12 highlighting that seizure risk is not restricted to CNS-targeted therapies.

Retrospective analyses highlight that the incidence of DIS within the clinical population is 0.8% to 1.7%^13-16 and is characterized by unintentional (e.g., unforeseen drug or drug-interaction effects, inadvertent overdose) and intentional (e.g., recreational or deliberate suicidal overdose of stimulants and/or narcotics)^17,18 risks. Phenotypically, DIS frequently present as generalized tonic–clonic seizures although partial seizures and convulsive and non-convulsive seizures or status epilepticus have also been reported.^14,19 Drug-induced seizure (of any phenotype) may occur within patients with no prior history or risk of seizures and should be differentiated from epileptic seizures which result from a genetic and/or non-genetic neurological disorder. Nevertheless, there is a lack of discernable EEG characteristics which differentiate DIS from epileptic seizures in non-clinical models that are available early in drug development. A greater understanding of the pathophysiology of DIS is essential for the development and risk assessment of the next generation of pharmaceuticals.

The pathophysiology of DIS is broadly characterized by patient- and drug-related factors.²⁰ Patient-related factors include age, hepatic or renal function, genetic susceptibility to seizure, and/or the seizurogenic potential of drugs. Likewise, drug-related factors associated with DIS include blood brain barrier penetration, on target and off-target pharmacological activity on brain receptors/proteins, drug class, dose level, route of administration, and lipid solubility, among others. Drug-related factors are of particular interest during drug development, since early attrition is preferable over late-phase attrition. Drug attrition rates related to neurological safety evaluations are relatively low preclinically³ and seizure liability risks may be investigated in early drug development.²¹

The etiology of DIS is largely understood to be a result of either a deficit in inhibitory (e.g., gamma aminobutyric acid ((GABA)) or elevation in excitatory (e.g., glutamate) signaling. How this altered neuronal signaling occurs and how these changes interact with other non-brain receptor driven DIS-associated changes such as metabolic failure, electrolyte disturbances, altered drug metabolism and withdrawal effects, as applicable, remain poorly described for most drugs. Accordingly, we aim to highlight molecular mechanisms involved in DIS of several known drugs and/or drug classes. Interestingly, the timing of seizures can help to identify the putative mechanism of action underlying the DIS. For instance, DIS due to acute disruption to synaptic neurotransmission or ion channel function typically occur when the concentration of the pharmacological compound is highest (Tmax), as is the case with clozapine.^22,23 Conversely, DIS originating from toxicity to neurons and cellular constituents can present delayed onset and is less predictable.^24,25

Altered Ion Channel Function/Neurotransmission

As there is no standard study design or guideline for evaluating preclinical seizure liability, a science-driven CNS safety testing strategy is typically used and comprehensive mechanistic investigations for potentially altered ion channel functions or neurotransmitter interferences are often considered a starting point in DIS investigations. The mechanisms underlying the origin of seizures may involve the regulation of neuron excitability as seen in some forms of epilepsy.²⁶ These can be broadly described as defects with either synaptic signaling²⁷ or intrinsic excitability.^28,29 At the synaptic level, changes to excitatory glutamatergic (e.g. α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/AMPA, N-Methyl-D-aspartate/NMDA, and kainate receptor) or inhibitory (e.g. GABA or glycine) synaptic signaling underlies the most frequent mechanistic targets for the origins of seizures.²⁷ Additionally, intrinsic excitability involves modulation of the functional properties of the voltage gated sodium (Na⁺), potassium (K⁺), and calcium (Ca²⁺) ion channels which are critical for action potential generation and propagation.³⁰ Thus, there is a large list of potential molecular targets which have been implicated in DIS and may be screened for the development of safe therapeutics.

One of the main causes of DIS is a reduction in the efficacy of inhibitory GABA signaling which can be associated with limiting presynaptic GABA neurotransmitter release or reducing postsynaptic GABA receptor function or expression. GABAergic neurotransmission involves the activation of inhibitory postsynaptic GABA receptors which are classified into two families based on their functional properties: ionotropic GABA_A and metabotropic GABA_B receptors.³¹ Adding further diversity to GABAergic signaling is that GABA_A receptors have two distinct pharmacologically relevant sites; the GABA binding site and the benzodiazepine binding site.³² The GABA_A receptor benzodiazepine binding site is only found on a subset of GABA_A receptors expressed regionally throughout the CNS.³³ Antagonism of GABA_A receptors has been reported as the cause of antibiotic induced seizures³⁴ as seen with the β-lactam family consisting of penicillin G,³⁵ cephalosporins,³⁶ and carbapenems.^37,38 Meanwhile, fluoroquinolones are known to cause seizures and likely do so through antagonizing GABA_B receptors and potentiating excitatory NMDA receptor currents.^39,40 Other mechanisms antagonizing GABA_A receptors and causing seizures include blocking the GABA_A receptor pore (picrotoxin),⁴¹ blocking the benzodiazepine binding site (flumazenil),⁴² or acting as GABA_A receptor negative allosteric modulators (bicuculline and gabazine).⁴³ Notably, drugs blocking the benzodiazepine site are challenging clinically as benzodiazepine administration is the preferred antiseizure treatment.⁴⁴ Finally, DIS can be elicited by synthetic opioids such has meperidine which cause a reduction in the synaptic release of GABA.⁴⁵

Potentiating the signaling of excitatory neurotransmission is another well-known cause of DIS. In non-clinical settings, direct activation of glutamatergic signaling by either kainic acid⁴⁶ or NMDA⁴⁷ can cause seizure activity. Clinically, clozapine is a widely prescribed antipsychotic medication used in the treatment of schizophrenia which exhibits strong relationship between serum concentration levels and seizure development risk.^22,23 Clozapine increases neuronal activity by promoting the glial release of D-serine, a co-agonist of excitatory NMDA receptors.⁴⁸ Similarly, opioid metabolites such as morphine-3-glucuronide have proconvulsant activity by acting indirectly to activate NMDA receptors.⁴⁹ In some cases, individual drugs can act on multiple ion channels concurrently to cause the onset of seizures through both short- and long-term effects. For example, many of the physiological effects of alcohol are due to acute and long-term effects on both GABA and NMDA receptors.⁵⁰ While acute alcohol ingestion inhibits NMDA receptor function,⁵⁰ chronic alcohol exposure increases the expression of NMDA receptors throughout the brain.^51,52 Moreover, GABA_A receptor expression is changed during chronic alcohol consumption with a reduction of synaptic α1 containing GABA receptors (the principal synaptic GABA receptor) and trafficking of α4 containing receptors out of the extrasynaptic space.⁵³ Ultimately, withdrawal from chronic alcohol exposure induces seizures due to circuit hyperexcitability through increased NMDA receptor expression and altered signaling properties of GABA-associated inhibition.⁵⁴

DIS can also arise from hyperexcitability due to changes in the properties of voltage gated ion channels. Unsurprisingly, broad spectrum K⁺ blockers such as 4-aminopyridine (4-AP), which is used to treat multiple sclerosis, must be used with caution since, although it is generally well-tolerated,⁵⁵ high concentrations have been known to cause seizures. Moreover, the seizurogenic properties of 4-AP are regularly used in fundamental research to induce seizure activity within animal models. Similarly, the local anesthetic lidocaine functions as a voltage gated Na⁺ channel blocker at lower concentrations (<10 μM) but, at high levels, is associated with increased seizure risk by selectively blocking inhibitory mechanisms.^56-62 Monoethylglycinexilidide (MEGX) and 2,6-glycine xylidide (GX) downstream metabolites of lidocaine have also been reported to lower seizure threshold^63,64 and potentiate lidocaine-induced seizures. Specifically, lidocaine has been shown to inhibit both the inhibitory action of cerebellar neurons on the vestibular nuclei,⁶⁵ as well as the L-glutamate-induced transcallosal inhibition of contralateral neurons in a GABA-independent manner.⁶⁶ Warnick et al.⁶⁶ (1971) also proposed that the proconvulsant effects of lidocaine is likely not via synaptic action, but may be due to its central local anesthetic action on the inhibitory fibers that are involved in direct cortical inhibition. Recent evidence suggests that the seizure inducing properties of lidocaine have been reported to be in part due to a dose dependent block of two-pore domain K⁺ channels (K_2P) (IC₅₀ 207 μM)⁶⁷ but the concentrations that are used clinically are lower and this would require dose levels in the toxicology range. Other local anesthetics such as bupivacaine, levobupivacaine, and ropivacaine have also been observed to inhibit K_2P channels in a similar dose dependent manner and are known to possess seizurogenic properties.⁶⁸

Neuronal Death And/or Injury

A large body of evidence supports the notion that spontaneous seizures can be brought on by the death of vulnerable neurons in the hippocampus and amygdala, which can alter the balance of excitation/inhibition in the limbic network.^24,25 Therapeutics which are commonly given at doses close to the toxic range, and/or have slow/impaired clearance, may cause higher rates of neuronal damage due to increased exposure as seen in several human case studies. For instance, many cancer therapies have been shown to induce seizures via neuronal damage, especially when given at high doses or in the presence of renal or hepatic disorders, where clearance of the drug is impaired.

Cisplatin, an effective and widely used antineoplastic agent in the treatment of solid tumors, has been demonstrated to induce encephalopathies and seizures in rare cases.⁶⁹ Cisplatin chemotherapy has been linked to the occurrences of two types of CNS disorder: posterior leukoencephalopathy syndrome, where patient exhibit abnormalities predominantly in the occipital lobes,^70-74 and focal neurological deficits.^75-78 It is proposed that these cisplatin-associated encephalopathies may be caused by vascular events that are generally not seen in cerebral imaging—a notion supported by studies where cisplatin was found to have high vascular toxicity, and was able to induce cerebrovascular ischemic events.⁷⁹ The mechanism of this vascular toxicity is still unknown, but may include cisplatin-induced hypomagnesemia or altered platelet aggregation.⁶⁹ In rare cases, oxaliplatin, which is an alkylating agent commonly used in the treatment of colorectal and gastric cancers, have also been shown to cause seizures either directly⁸⁰ or as a result of posterior reversible leukoencephalopathy syndrome (PRES),⁸¹ possibly via vascular effects.^82,83 In addition, cyclosporine, a commonly used immunosuppressive agent, can cause a form of posterior reversible encephalopathy syndrome, similar to those caused by cisplatin.⁸⁴ Seizures due to cyclosporine neurotoxicity have been proposed to result from a variety of causes such as endothelial damage and the release of endothelin-1, a potent vasoconstrictor,^85-87 or a direct effect on neuronal excitability.⁸⁸

Similarly, intrathecal and intravenous treatment with methotrexate, an antimetabolite that is a competitive inhibitor of the enzyme dihydrofolate reductase, has also been shown to cause seizures and subcortical encephalopathy that may be ischemic in origin.^89-92 Mineralizing microangiopathy were shown in pathological specimens obtained on autopsy of those who received methotrexate alone (along) or in combination with radiotherapy, which supports the theory that methotrexate-induced encephalopathy has a vascular origin.⁹² As well, interferon-α treatment has been reported to induce seizures in 1–4% of patients.^93-95 Its toxicity has been attributed to mechanisms such as the disruption of the blood brain barrier and subsequently inducing vasogenic brain edemas.⁹⁶

Busulfan is an alkylating agent that is traditionally used to treat chronic myeloid leukemia as well as used in the myeloablative regimen of bone marrow transplantations.⁹⁷ The neurotoxicity of busulfan has been established previously,^98-100 and in particular, busulfan-associated seizures and abnormalities on EEG have been described.¹⁰¹ While the mechanism of busulfan-induced neurotoxicity is unclear, Kobayashi et al (1998)¹⁰¹ speculated that as busulfan is known to bind tightly to plasma proteins and thus can easily cross the blood brain barrier soon after administration, convulsions could be due to prolonged brain exposure to busulfan and/or its metabolites causing transient and self-limiting excitotoxic neuronal injury (Table 1).

Table 1.

A list of known drugs with risk for the development of DIS and their targets.

Treatment type	Name	Mechanism	Estimation of risk^a
Alcohol	N/A	Increase NMDA receptors, change GABA receptor expression profile	N/A
Anesthesia/Pain management	Opioids (metabolites)	NMDA signaling	Low
Anesthesia/Pain management	Opioids (meperidine)	NMDA signaling	High
Antibiotic	Penicillin	GABA signaling	High
	Cephalosporin	GABA signaling	Medium
	Carbapemes	GABA signaling	Medium
	Fluroquinolones	GABA signaling	Medium
Antipsychotic	Clozapine	NMDA signaling	High
Benzodiazepine antagonist	Flumanazil	GABA signaling	High
Chemotherapeutic	Cisplatin	Neurotoxicity (vascular toxicity)	Medium
	Oxaliplatin	Posterior reversible leukoencephalopathy syndrome	Medium
	Interferon^a	Neurotoxic, vasoconstriction	Medium
	Busulfan	Unknown	Medium
	5-fluorouracil	Ammonia toxicity	Medium
Chemotherapeutic (antimetabolite)	Methotrexate	Neurotoxic, vasoconstriction	Medium
Immunosuppressive	Cyclosporin	Neurotoxicity (vasoconstriction release of endothelin-1), neuronal excitability	Medium
Local anesthetic	Lidocaine	Na+/K+ channels	Low
Multiple sclerosis	Fampridine (4-aminopyridine)	K+ channel blocker	N/A
Nonsteroidal anti-inflammatory drugs (NSAIDs)	Ibuprofen, pyrazolons, acetic acid, and anthranilic acids	Unknown (proposed impaired prostaglandin/thromboxane production)	Low
Primarily research	Gabazine	GABA signaling	N/A
	Bicuculine	GABA signaling	N/A
	Picrotoxin	GABA signaling	N/A

N/A, Not applicable.

^a11, DIS, drug-induced seizure.

5-fluorouracil is an antimetabolite that is widely used as a chemotherapeutic agent in the treatment of various cancers. High-dose administration of 5-fluorouracil has been previously reported to cause encephalopathy—report, in some cases, to be up to 5.7% of patients—with severe symptoms of stupor, coma, and/or seizures concurrently with hyperammonaemia and lactic acidosis.¹⁰² Although direct evidence is lacking, it is postulated that high 5-fluorouracil dosage may induce the accumulation of ammonia (an end product of 5-fluorouracil metabolism). This ammonia would be normally cleared by the ATP-dependent urea cycle, but fluroacetate, the intermediate product of 5-fluorouracil, is known to inhibit the ATP producing Kreb’s cycle and results in lactic acidosis and the impairment of the ATP-dependent urea cycle.¹⁰³ Accordingly, a transient hyperammonaemia state with encephalopathy may arise.¹⁰² Additionally, 5-fluorouracil toxicity has been linked to an inhibited deficiency of the enzyme dihydropyrimidine dehydrogenase, due to genetic mutations in the protein of which at least 23 different polymorphisms have been discovered.¹⁰⁴ As this enzyme in involved in the breakdown of 5-fluorouracil, its deficiency can lead to toxic accumulations of the drug. In one report, a polymorphism of dihydropyrimidine dehydrogenase was associated with multiorgan failure, seizures, myoclonus, and encephalopathy after 5-fluorouracil treatment.¹⁰⁵

Other Mechanisms Associated With Drug-Induced Seizures

In rare cases, the ingestion of therapeutic doses of nonsteroidal anti-inflammatory drugs (NSAIDs) such as propionic acid derivatives (ibuprofen), pyrazolones (phenylbutazone), acetic acid derivatives (diclofenac and indomethacin), and anthranilic acids (mefenamic acid and meclofenamate) have been associated with seizures.^106,107 While the exact mechanism by which NSAIDs induces seizures is unknown, the ability of NSAIDs to interfere and inhibit cerebral arachidonic acid metabolism—which lowers the seizure threshold—has been proposed as a possible explanation.¹⁰⁶ In support of this theory, changes in the levels of prostaglandin and/or thromboxane, both products of the arachidonic acid metabolism pathway, have been implicated in the appearance of convulsions and seizures.^106,108 Neuronal prostaglandin, in particular, has been previously shown to be essential for seizure suppression and the regulation of sleep that follows seizures via the activation of prostaglandin D receptor (DP₁R).^109-111

Hypoglycemia was historically identified as a risk factor for seizures but more recent data suggests that seizures induced by hypoglycemia are rare.¹¹² Hyperthermia is known to cause febrile seizures in a proportion of the population¹¹³ most likely by acting on NMDA and GABA related pathways.¹¹⁴ Electrolyte disturbances such as hyponatremia, hypocalcemia, and hypomagnesemia are also well characterized changes associated with seizures and may be identified by clinical chemistry investigations when conducting non-clinical neurotoxicity studies.¹¹⁵

Considerations Related to Drug Development and Seizure Risk Characterization

Once a seizure risk is identified often in toxicology or safety pharmacology studies, characterization of this liability may be an important part of the neurotoxicology investigation. The use of a range of non-clinical models can help predict safety margins of the new chemical entity (NCE) in humans and this integrated risk assessment is pivotal in drug development. Drugs with safety margins based on exposure ≥10X generally progress through development with minimal regulatory concerns since the dose dependence of seizurogenic effects is a widely accepted concept. Non-clinical animal models (i.e., not genetically modified) that are used to evaluate the potential for a NCE to cause seizurogenic activity differentiate between simple epileptiform activity and the spectrum of limited to severe DIS (unpublished data) but the severity observed in these non-clinical models may not translate to the DIS liability observed clinically. Sensitivity to seizurogenic effects differ between species in the following order beagle dogs > rodents and cynomolgus monkeys > Göttingen minipigs with a more than 2-fold difference between canines and minipigs.^{11,21,116,117} Understanding the clinical signs that may precede seizures can help develop a monitoring strategy for clinical trials. While premonitory clinical signs often differ between drugs, the clinical sign profile (types of clinical signs and time/exposure from clinical sign onset to seizure) tends to be similar for a given NCE with common trends also observed between species.¹¹⁸ Abnormal EEG morphologies (e.g., interictal epileptiform activity) are often observed in the absence of concurrent clinical signs but most animals presenting drug-induced interictal activity will also present typical clinical signs and epileptiform EEG morphologies, simultaneously. The seizure risk associated with specific clinical signs such as myoclonus, myoclonic jerks, and tremors also differs greatly. Myoclonus and myoclonic jerks in conscious/awake animals are frequently associated with abnormal epileptiform EEG activity during the conduct of non-clinical neurotoxicology studies.¹¹⁸ In contrast, myoclonus or myoclonic jerks during sleep (especially during sleep onset) are often physiological and are typically not associated with abnormal EEG activity.¹¹⁹ Low amplitude tremors can be observed in normal healthy animals and are not associated with abnormal EEG activity in most cases. It remains that tremors may be associated with drug-induced abnormal epileptiform EEG activity in some cases and video-EEG recorded by telemetry can be used to characterize background CNS clinical signs from premonitory changes.¹¹⁸ A wide range of DIS assays can be considered from early screening panels¹²⁰ to ex-vivo electrophysiology¹²¹ and ultimately EEG models sometimes with seizure threshold tests.^118,122 Some programs will only require minimal DIS investigations with a single assay while others will require a more comprehensive characterization of this potential liability based on a perceived higher risk or regulatory interactions.

Conclusions

Neurotransmitter mediated effects, ion channel alterations, cell damages and necrosis are only a few of the potential mechanisms involved with DIS (Figure 1). While characterization of molecular mechanisms involved with DIS can help during risk assessment and can further define translational considerations, the complexity of the neurotoxicity underlying DIS often precludes from clearly defining the pathway(s) involved with DIS. Although a perturbation of the excitation-inhibition balance is a commonality across several mechanisms, a definitive understanding of the root causes of DIS is often difficult to ascertain due to the complex nature of the neuronal network functions. In vitro electrophysiological investigations may provide an early stage screen for DIS risk owing to their ability to help define these alterations in the neuronal excitation-inhibition balance. However, these early stage in vitro assessments possess technical limitations which typically need to be complimented with in vivo investigations to characterize the DIS risk. For instance, long-term in vivo studies employing EEG telemetry may be required to identify potential seizurogenic liabilities resulting from prolonged drug exposure that cannot be plausibly assessed through acute in vitro exposures or via monosynaptic assessments of in vitro drug effects. Likewise, DIS caused by long-term changes to brain function, neuronal injury or cell death may also necessitate extensive toxicology studies highlighting the need for a wide array of both in vitro and in vivo seizurogenic risk assessments. In many cases, defining safety margins, precursor clinical and EEG signs, reversibility, dose dependence, and the nature of the neurological effects is adequate to complete an acceptable safety assessment. Several approved drugs present a DIS liability and a range of testing strategies can be considered to conceive an integrated risk assessment plan adapted to the specifics of the program. Drug-induced seizure investigations, like most other safety testing areas, benefits from scientifically driven study designs and multi-disciplinary analyses.

Figure 1.

An illustration highlighting the mechanisms of drug-induced seizure. (A) Impacts to metabolic pathways. (B) Changes to synaptic neurotransmitter release. (C) Cell death due to neurotoxicity. (D), (E). Altered function/expression of synaptic receptor proteins. (F) Altered function/expression of voltage gated ion channels.

Footnotes

Acknowledgments

The authors would like to thank Kelly Bullock for providing the illustration in .

Declaration of Conflicting of Interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Simon Authier

References

Arrowsmith

Miller

. Phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov. 2013;12:569.

Pangalos

Schechter

Hurko

. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov. 2007;6:521-532.

Weaver

Valentin

J-P

. Today’s challenges to de-risk and predict drug safety in human “Mind-the-Gap”. Toxicol Sci. 2019;167:307-321.

Thomas

Burns

Audette

Carroll

Dow-Hygelund

Hay

. Clinical Development Success Rates 2006–2015. San Diego, Washington, DC: Biomedtracker/BIO/Bend: Amplion; 2016.

ICH. ICH S7A . Safety Pharmacology studies for human pharmaceuticals. In: Evaluation of Medicines for Human Use. CPMP/ICH/539/00. London: European Agency for the Evaluation of Medicinal Products; 2000. Accessed November 16, 2000.

Sam

Salem

Ghatei

. Rimonabant: From RIO to Ban. J Obes. 2011;2011:432607.

Kaitin

Milne

. A dearth of new meds. Sci Am. 2011;305:16.

Aagaard

Hansen

. Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011. BMC Pharmacol Toxicol. 2013;14:30.

Authier

Arezzo

Delatte

, et al. Safety pharmacology investigations on the nervous system: An industry survey. J Pharmacol Toxicol Methods. 2016;81:37-46.

10.

Bass

Kinter

Williams

. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods. 2004;49:145-151.

11.

Murphy

Delanty

. Drug-Induced Seizures. CNS Drugs. 2000;14:135-146.

12.

Accardi

Pugsley

Forster

Troncy

Huang

Authier

. The emerging role of in vitro electrophysiological methods in CNS safety pharmacology. J Pharmacol Toxicol Methods. 2016;81:47-59.

13.

Neligan

. Drug-induced seizures. In: Shorvon

Andermann

Guerrini

, eds. The Causes of Epilepsy: Common and Uncommon Causes in Adults and Children. Cambridge: Cambridge University Press; 2011:664-673.

14.

Zutshi

. Medication-induced seizures and status epilepticus. In: Husain

Sinha

, eds. Continuous EEG Monitoring: Principles and Practice. Cham: Springer International Publishing; 2017:361-382.

15.

Porter

Jick

. Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms. Lancet. 1977;309:587-588.

16.

Program

BCS

. Drug-induced convulsions. Lancet. 1972;300:677-679.

17.

Smith

PEM

McBride

. Illicit drugs and seizures. Seizure. 1999;8:441-443.

18.

Thundiyil

Rowley

Papa

Olson

Kearney

. Risk factors for complications of drug-induced seizures. J Med Toxicol. 2011;7:16-23.

19.

Messing

Closson

Simon

. Drug-induced seizures: a 10-year experience. Neurology. 1984;34:1582.

20.

Ruffmann

Bogliun

Beghi

. Epileptogenic drugs: a systematic review. Expert Rev Neurother. 2006;6:575-589.

21.

Accardi

Huang

Authier

. Seizure liability assessments using the hippocampal tissue slice: comparison of non-clinical species. J Pharmacol Toxicol Methods. 2018;93:59-68.

22.

Varma

Bishara

Besag

FMC

Taylor

. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol. 2011;1:47-66.

23.

Williams

Park

. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs. 2015;29:101-111.

24.

Sloviter

. The functional organization of the hippocampal dentate gyrus and its relevance to the pathogenesis of temporal lobe epilepsy. Ann Neurol. 1994;35:640-654.

25.

Baram

Jensen

Brooks-Kayal

. Does acquired epileptogenesis in the immature brain require neuronal death? Epilepsy Curr. 2011;11:21-26.

26.

Oyrer

Maljevic

Scheffer

Berkovic

Petrou

Reid

. Ion channels in genetic epilepsy: from genes and mechanisms to disease-targeted therapies. Pharmacol Rev. 2018;70:142-173.

27.

Fukata

. Epilepsy and synaptic proteins. Curr Opin Neurobiol. 2017;45:1-8.

28.

Kaplan

Isom

Petrou

. Role of sodium channels in epilepsy. Cold Spring Harb Perspect Med. 2016;6:a022814.

29.

Köhling

Wolfart

. Potassium channels in epilepsy. Cold Spring Harb Perspect Med. 2016;6:a022814.

30.

Alexander

RPD

Mitry

Sareen

Khadra

Bowie

. Cerebellar stellate cell excitability is coordinated by shifts in the gating behavior of voltage-gated Na+ and A-type K+ channels. eNeuro. 2019;6:0126.

31.

Bowery

Smart

. GABA and glycine as neurotransmitters: a brief history. Br J Pharmacol. 2006;147:S109-S119.

32.

Jacob

Moss

Jurd

. GABAA receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat Rev Neurosci. 2008;9:331-343.

33.

Olsen

Sieghart

. International union of pharmacology. LXX. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev. 2008;60:243-260.

34.

Wanleenuwat

Suntharampillai

Iwanowski

. Antibiotic-induced epileptic seizures: Mechanisms of action and clinical considerations. Seizure. 2020;81:167-174.

35.

Wallace

. Antibiotic-induced convulsions. Crit Care Clin. 1997;13:741-762.

36.

Sugimoto

Uchida

Mashimo

, et al. Evidence for the involvement of GABAA receptor blockade in convulsions induced by cephalosporins. Neuropharmacology. 2003;45:304-314.

37.

De Sarro

Ammendola

Nava

De Sarro

. Effects of some excitatory amino acid antagonists on imipenem-induced seizures in DBA/2 mice. Brain Res. 1995;671:131-140.

38.

Miller

Ball

Bookstaver

Dornblaser

Bennett

. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011;31:408-423.

39.

Akahane

Kato

Takayama

. Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice. Antimicrob Agents Chemother. 1993;37:1764-1770.

40.

Bellon

Perez-Garcia

Coverdale

Chacko

. Seizures associated with levofloxacin: case presentation and literature review. Eur J Clin Pharmacol. 2009;65:959-962.

41.

Olsen

. Picrotoxin-like channel blockers of GABAA receptors. Proc Natl Acad Sci Unit States Am. 2006;103:6081-6082.

42.

Zhu

Noviello

Teng

Walsh

Kim

Hibbs

. Structure of a human synaptic GABAA receptor. Nature. 2018;559:67-72.

43.

Ueno

Bracamontes

Zorumski

Weiss

Steinbach

. Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABAAReceptor. J Neurosci. 1997;17:625-634.

44.

Chen

H-Y

Albertson

Olson

. Treatment of drug-induced seizures. Br J Clin Pharmacol. 2016;81:412-419.

45.

Vaughan

Ingram

Connor

Christie

. How opioids inhibit GABA-mediated neurotransmission. Nature. 1997;390:611-614.

46.

Lévesque

Avoli

. The kainic acid model of temporal lobe epilepsy. Neurosci Biobehav Rev. 2013;37:2887-2899.

47.

Stafstrom

Sasaki-Adams

. NMDA-induced seizures in developing rats cause long-term learning impairment and increased seizure susceptibility. Epilepsy Res. 2003;53:129-137.

48.

Tanahashi

Yamamura

Nakagawa

Motomura

Okada

. Clozapine, but not haloperidol, enhances glial d-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol. 2012;165:1543-1555.

49.

Hemstapat

Monteith

Smith

a. MT

. Morphine-3-glucuronide’s neuro-excitatory effects are mediated via indirect activation of N-Methyl-d-Aspartic acid receptors: mechanistic studies in embryonic cultured hippocampal neurones. Anesth Analg. 2003;97:494-505.

50.

Harrison

Skelly

Grosserode

, et al. Effects of acute alcohol on excitability in the CNS. Neuropharmacology. 2017;122:36-45.

51.

Snell

Nunley

Lickteig

Browning

Tabakoff

Hoffman

. Regional and subunit specific changes in NMDA receptor mRNA and immunoreactivity in mouse brain following chronic ethanol ingestion. Mol Brain Res. 1996;40:71-78.

52.

Kalluri

HSG

Mehta

Ticku

. Up-regulation of NMDA receptor subunits in rat brain following chronic ethanol treatment. Mol Brain Res. 1998;58:221-224.

53.

Liang

Cagetti

Olsen

Spigelman

. Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence. J Pharmacol Exp Therapeut. 2004;310:1234-1245.

54.

Hughes

. Alcohol withdrawal seizures. Epilepsy Behav. 2009;15:92-97.

55.

Jensen

Ravnborg

Dalgas

Stenager

. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2014;7:97-113.

56.

Pfeifer

Greenblatt

Koch-Weser

. Clinical use and toxicity of intravenous lidocaine. Am Heart J. 1976;92:168-173.

57.

Usubiaga

Wikinski

Ferrero

Usubiaga

Wikinski

. Local anesthetic-induced convulsions in man. Anesth Analg. 1966;45:611-620.

58.

Garcia

Alldredge

. Drug-induced seizures. Neurol Clin. 1994;12:85-100.

59.

Julien

. Lidocaine in experimental epilepsy: correlation of anticonvulsant effect with blood concentrations. Electroencephalogr Clin Neurophysiol. 1973;34:639-645.

60.

Taverner

Bain

. Intravenous lignocaine as an anticonvulsant in status epilepticus and serial epilepsy. Lancet. 1958;272:1145-1147.

61.

Bernhard

Bohm

. The action of local anaesthetics on experimental epilepsy in cats and monkeys. Br J Pharmacol Chemother. 1955;10:288-295.

62.

DeToledo

. Lidocaine and seizures. Ther Drug Monit. 2000;22:320-322.

63.

Blumer

Strong

Atkinson

Jr . The convulsant potency of lidocaine and its N-dealkylated metabolites. J Pharmacol Exp Therapeut. 1973;186:31-36.

64.

Smith

Duce

. The acute antiarrhythmic and toxic effects in mice and dogs of 2-ethylamino-2’,6-‘acetoxylidine (L-86), a metabolite of lidocaine. J Pharmacol Exp Therapeut. 1971;179:580-585.

65.

Sangiah

Garrison

Nichols

Yim

GKW

. Rhythmic firing of Deiters’ neurons and synchronization by cerebellar inhibition in lidocaine-treated cats. Brain Res. 1975;93:409-418.

66.

Warnick

Kee

Yim

GKW

. The effects of lidocaine on inhibition in the cerebral cortex. Anesthesiology. 1971;34:327-332.

67.

Nayak

Harinath

Nama

Somasundaram

Sikdar

. Inhibition of human two-pore domain K+ channel TREK1 by local anesthetic lidocaine: negative cooperativity and half-of-sites saturation kinetics. Mol Pharmacol. 2009;76:903-917.

68.

Shin

Soh

Kim

, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth. 2014;28:81-86.

69.

Steeghs

de Jongh

Smitt

PAES

Bent

MJv. d.

. Cisplatin-induced encephalopathy and seizures. Anti Canc Drugs. 2003;14:443-446.

70.

Berman

Mann

. Seizures and transient cortical blindness associated with cis-platinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer. 1980;45:764-766.

71.

van Gelder

Geurs

Kho

Dippel

DWJ

Vecht

Splinter

TAW

. Cortical blindness and seizures following cisplatin treatment: both of epileptic origin? Eur J Canc. 1993;29:1497-1498.

72.

Highley

Meller

Pinkerton

. Seizures and cortical dysfunction following high-dose cisplatin administration in children. Med Pediatr Oncol. 1992;20:143-148.

73.

Philip

Carmichael

Harris

. Convulsions and transient cortical blindness after cisplatin. BMJ. 1991;302:416.

74.

Cattaneo

Filipazzi

Piazza

Damiani

Mancarella

. Transient blindness and seizure associated with cisplantin therapy. J Canc Res Clin Oncol. 1988;114:528-530.

75.

Bellin

Selim

. Cisplatin-induced hypomagnesemia with seizures: a case report and review of the literature. Gynecol Oncol. 1988;30:104-113.

76.

Brauers

Mattelaer

Mersdorf

Wang

. Seizures associated with cisplatin administration. Eur Urol. 1997;32:118-120.

77.

Gorman

Kefford

Stuart‐Harris

. Focal encephalopathy after cisplatin therapy. Med J Aust. 1989;150:399-401.

78.

Mead

Arnold

Green

Macbeth

Williams

Whitehouse

. Epileptic seizures associated with cisplatin administration. Canc Treat Rep. 1982;66:1719-1722.

79.

Içli

Karaoğuz

Dinçol

, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993;72:587-593.

80.

Rahal

Truong

Kallail

. Oxaliplatin-induced tonic-clonic seizures. Case Rep Oncol Med. 2015;2015:879217.

81.

Janjua

Hassan

Afridi

Zahid

. Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES). BMJ Case Rep. 2017;2017:bcr2017221571.

82.

Tamaki

Sadoshima

Baumbach

Iadecola

Reis

Heistad

. Evidence that disruption of the blood-brain barrier precedes reduction in cerebral blood flow in hypertensive encephalopathy. Hypertension (Dallas). 1984;6:I75-I81.

83.

Bartynski

. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol. 2008;29:1043-1049.

84.

Singh

Rees

Sander

. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatr. 2007;78:342-349.

85.

Bloom

Bentley

Garrison

. Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. Surgery. 1993;114:480-488.

86.

Haug

Duell

Lenich

Kolb

Grünert

. Elevated plasma endothelin concentrations in cyclosporine-treated patients after bone marrow transplantation. Bone Marrow Transplant. 1995;16:191-194.

87.

Gijtenbeek

JMM

van den Bent

Vecht

. Cyclosporine neurotoxicity: a review. J Neurol. 1999;246:339-346.

88.

Serkova

Christians

Benet

. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv. 2004;4:97-107.

89.

Finkelstein

Zevin

Heyd

Bentur

Zigelman

Hersch

. Emergency treatment of life-threatening intrathecal methotrexate overdose. Neurotoxicology. 2004;25:407-410.

90.

Rollins

Winick

Bash

Booth

. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. AJNR. Am J Neuroradiol. 2004;25:1688-1695.

91.

Lövblad

K-O

Kelkar

Ozdoba

Ramelli

Remonda

Schroth

. Pure methotrexate encephalopathy presenting with seizures: CT and MRI features. Pediatr Radiol. 1998;28:86-91.

92.

Price

Birdwell

. The central nervous system in childhood leukemia.III. Mineralizing microangiopathy and dystrophic calcification. Cancer. 1978;42:717-728.

93.

Janssen

HLA

Berk

Vermeulen

Schalm

. Seizures associated with low-dose α-interferon. Lancet. 1990;336:1580.

94.

Shakil

Di Bisceglie

Hoofnagle

. Seizures during alpha interferon therapy. J Hepatol. 1996;24:48-51.

95.

Woynarowski

Socha

. Seizures in children during interferon alpha therapy. J Hepatol. 1997;26:956-957.

96.

Pavlovsky

Seiffert

Heinemann

Korn

Golan

Friedman

. Persistent BBB disruption may underlie alpha interferon-induced seizures. J Neurol. 2005;252:42-46.

97.

La Morgia

Mondini

Guarino

Bonifazi

Cirignotta

. Busulfan neurotoxicity and EEG abnormalities: a case report. Neurol Sci. 2004;25:95-97.

98.

deMagalhaes-Silverman

Bloom

Donnenberg

, et al. Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies. Bone Marrow Transplant. 1996;17:329-333.

99.

Antonini

Ceschin

Morino

, et al. Early neurologic complications following allogeneic bone marrow transplant for leukemia: a prospective study. Neurology. 1998;50:1441-1445.

100.

De La Camara

Tomas

Figuera

Berberana

Fernandez-Rañada

. High dose busulfan and seizures. Bone Marrow Transplant. 1991;7:363-364.

101.

Kobayashi

Watanabe

Iguchi

, et al. Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation. Bone Marrow Transplant. 1998;21:217-220.

102.

Yeh

Cheng

. High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Canc. 1997;75:464-465.

103.

Koenig

Patel

. Biochemical basis for fluorouracil neurotoxicity. Arch Neurol. 1970;23:155-160.

104.

van Kuilenburg

ABP

De Abreu

van Gennip

. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem. 2003;40:41-45.

105.

Lazar

Mau-Holzmann

Kolb

Reichenmiller

Riess

Schömig

. Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Oncol Res Treat. 2004;27:559-562.

106.

Steinhauer

Hertting

. Lowering of the convulsive threshold by non-steroidal anti-inflammatory drugs. Eur J Pharmacol. 1981;69:199-203.

107.

Auriel

Regev

Korczyn

. Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handb Clin Neurol. 2014;119:577-584.

108.

Sánchez-hernandez

Delgado

Navarro

Orta

Hernandez

Conde

. Seizures induced by NSAID. Allergy. 1999;54:90-91.

109.

Kaushik

Aritake

Kamauchi

, et al. Prostaglandin D2 is crucial for seizure suppression and postictal sleep. Exp Neurol. 2014;253:82-90.

110.

Akarsu

Mamuk

Comert

. Inhibition of pentylenetetrazol-induced seizures in rats by prostaglandin D2. Epilepsy Res. 1998;30:63-68.

111.

Förstermann

Heldt

Hertting

. Effects of intracerebroventricular administration of prostaglandin D2 on behaviour, blood pressure and body temperature as compared to prostaglandins E2 and F2 alpha. Psychopharmacology. 1983;80:365-370.

112.

Halawa

Zelano

Kumlien

. Hypoglycemia and risk of seizures: a retrospective cross-sectional study. Seizure. 2015;25:147-149.

113.

Dubé

Brewster

Baram

. Febrile seizures: mechanisms and relationship to epilepsy. Brain Dev. 2009;31:366-371.

114.

Ouardouz

Lema

Awad

Di Cristo

Carmant

. N-methyl-d-aspartate, hyperpolarization-activated cation current (Ih) and γ-aminobutyric acid conductances govern the risk of epileptogenesis following febrile seizures in rat hippocampus. Eur J Neurosci. 2010;31:1252-1260.

115.

Nardone

Brigo

Trinka

. Acute symptomatic seizures caused by electrolyte disturbances. J Clin Neurol. 2016;12:21.

116.

DaSilva

Breidenbach

Deats

, et al. Nonclinical species sensitivity to convulsions: An IQ DruSafe consortium working group initiative. J Pharmacol Toxicol Methods. 2020;103:106683.

117.

Kasteel

Westerink

. Refining in vitro and in silico neurotoxicity approaches by accounting for interspecies and interindividual differences in toxicodynamics. Expet Opin Drug Metabol Toxicol. 2021:1-11.

118.

Authier

Arezzo

Pouliot

, et al. EEG: Characteristics of drug-induced seizures in rats, dogs and non-human primates. J Pharmacol Toxicol Methods. 2019;97:52-58.

119.

Kojovic

Cordivari

Bhatia

. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther Adv Neurol Disord. 2011;4:47-62.

120.

Roberts

Authier

Mellon

, et al. Can we panelize seizure? Toxicol Sci. 2021;179:3-13.

121.

Miraucourt

Accardi

Asin

Pugsley

Curtis

Authier

. The application of electrophysiological methods to characterize AMPA receptors in dissociated adult rat and non-human primate cerebellar neurons for use in neuronal safety pharmacology assessments of the central nervous system. J Pharmacol Toxicol Methods. 2020;105:106883.

122.

Bassett

Troncy

Pouliot

Paquette

Ascah

Authier

. Telemetry video-electroencephalography (EEG) in rats, dogs and non-human primates: methods in follow-up safety pharmacology seizure liability assessments. J Pharmacol Toxicol Methods. 2014;70:230-240.

Drug-Induced Seizures: Considerations for Underlying Molecular Mechanisms

Abstract

Keywords

Introduction

Drug-Induced Seizures

Altered Ion Channel Function/Neurotransmission

Neuronal Death And/or Injury

Other Mechanisms Associated With Drug-Induced Seizures

Considerations Related to Drug Development and Seizure Risk Characterization

Conclusions

Footnotes

Acknowledgments

Declaration of Conflicting of Interest

Funding

ORCID iD

References